Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Oratz

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccineJ C Bystryn, A Zeleniuch-Jacquotte, R Oratz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factorA Chachoua, R Oratz, R Hoogmoed, et al.
Journal of Biological Response Modifiers|August 1, 1990
Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trialR Oratz, J L Speyer, J C Wernz, et al.
Cancer|March 15, 1988
Immunogenicity of a polyvalent melanoma antigen vaccine in humansJ C Bystryn, R Oratz, M N Harris, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1994
Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanomaA Chachoua, R Oratz, L Liebes, et al.
International Journal of Cancer|November 5, 1997
Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccineS R Reynolds, R Oratz, R L Shapiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 1998
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patientsS R Reynolds, E Celis, A Sette, et al.
Journal of Immunological Methods|October 18, 2000
Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysisS R Reynolds, E Celis, A Sette, et al.
Cancer|January 15, 1995
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccineK Miller, G Abeles, R Oratz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapyS Demaria, M D Volm, R L Shapiro, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccineJ C Bystryn, A Zeleniuch-Jacquotte, R Oratz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factorA Chachoua, R Oratz, R Hoogmoed, et al.
Journal of Biological Response Modifiers|August 1, 1990
Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trialR Oratz, J L Speyer, J C Wernz, et al.
Cancer|March 15, 1988
Immunogenicity of a polyvalent melanoma antigen vaccine in humansJ C Bystryn, R Oratz, M N Harris, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1994
Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanomaA Chachoua, R Oratz, L Liebes, et al.
International Journal of Cancer|November 5, 1997
Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccineS R Reynolds, R Oratz, R L Shapiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 1998
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patientsS R Reynolds, E Celis, A Sette, et al.
Journal of Immunological Methods|October 18, 2000
Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysisS R Reynolds, E Celis, A Sette, et al.
Cancer|January 15, 1995
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccineK Miller, G Abeles, R Oratz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapyS Demaria, M D Volm, R L Shapiro, et al.
Pageof 3